FDA vydala varovanie spoločnosti Novo Nordisk v súvislosti s inšpekciou v USA v roku 2025.[4] The FDA sent warning letters to 30 telehealth firms for making misleading claims about compounded versions of GLP-1 drugs, including Novo Nordisk's semaglutide and Eli Lilly's tirzepatide.[3] These companies labeled the compounded products as "generic Zepbound" or "generic Mounjaro" without indicating that they were compounded drugs.[3] The FDA emphasized that compounded drugs are not approved and are not the same as generics.[3] Novo Nordisk expects an FDA decision on the higher dose of 7.2 mg semaglutide for Wegovy in the first quarter of 2026.[1] The company issued a weak forecast for 2026, with sales down 5-13% and operating profit down 13% due to pricing pressure, increasing competition and patent expirations outside the US.[1] Shares of Novo Nordisk fell 4.5% in premarket trading after falling more than 14% on Tuesday.[1] In 2025, the company achieved net sales of DKK 309.06 billion, up 6% from the previous year, but below analysts' expectations.[1]